TScan Therapeutics

Founded 2018 · CIK 0001783328 · Biotech · Public

Platform for discovering T-cell receptor and target pairs to develop cancer immunotherapies

tscan.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$123M
2 Form D · Jan 2021
69 months since last filing
Contracts
—
No federal contracts on record
Patents
40
0 granted · 40 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$23,300,000
Private capital raisedForm D · SEC$100,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1252Escape Bio—$124M
1253B-TECH CONSULTING, LTD——
1254MIND BIOSCIENCES LLC——
1255TScan Therapeutics—$123M
1256Aardvark Therapeutics, Inc.—$103M
1257Satellite Biosciences, Inc.—$101M
1258GPN THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 13 related persons
  • Timothy BarberichDirector
  • Robert CraneExecutive Officer
  • Doug FambroughDirector
  • Lea HachigianDirector
  • Ittai HarelDirector
  • Andrew HedinDirector
  • Steve KrausDirector
  • Campbell MurrayDirector
  • Nandita ShangariDirector
  • Brian SilverDirector
  • Hannes SmarasonDirector
  • David SouthwellDirector · Executive Officer
  • Christoph WestphalDirector

Patents

USPTO · 0 granted of 40
  • Multiplexed T Cell Receptor Compositions, Combination Therapies, And Uses Thereofapplication
  • Prame Immunogenic Peptides, Binding Proteins Recognizing Prame Immunogenic Peptides, And Uses Thereofapplication
  • Binding Proteins Recognizing HA-2 Antigen And Uses Thereofapplication
  • Binding Proteins Recognizing HA-1 Antigen And Uses Thereofapplication
  • Compositions And Methods For Identifying Epitopesapplication
  • Binding Proteins Recognizing HPV16 E7 Antigen And Uses Thereofapplication
  • MAGEA1 Immunogenic Peptides, Binding Proteins Recognizing MAGEA1 Immunogenic Peptides, And Uses Thereofapplication
  • Binding Proteins Recognizing CD45 Immunogenic Peptides And Uses Thereofapplication
  • Use Of Binding Proteins For Treatment Of Solid Tumorsapplication
  • Use Of ANTI-HA-1 And ANTI-HA-2 Binding Proteins For Treatment Of Aml, All, And Mdsapplication
  • Binding Proteins Recognizing MAGEA4 Immunogenic Peptides And Uses Thereofapplication
  • Use Of ANTI-HA-1 And ANTI-HA-2 Binding Proteins For Treatment Of Aml, All, And Mdsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.